BT-001 is under clinical development by BioInvent International and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BT-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BT-001 is under development for the treatment of solid tumors including merkel cell carcinoma, soft tissue sarcoma, bone sarcoma, melanoma, triple-negative breast cancer (TNBC), non-small cell lung cancer and non-Hodgkin lymphoma. The drug candidate acts by targeting the cells expressing CTLA4 and cytokine GM-CSF. The drug candidate is a next generation oncolytic viruses expressing an anti-CTLA-4 antibody developed based on the Invir.IO, n-CoDeR and FIRST platforms. It is administered through intratumor route.
BioInvent International overview
BioInvent International (BioInvent) focuses on the research and development of antibodies for the treatment of cancer. The company uses n-CoDeR, an inhouse platform for developing immuno-oncology drugs. n-CoDeR is an antibody library used for the rapid selection, screening and identification of antibodies. The company’s pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin’s lymphoma and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers. Titan has collaborations and partners with several leading pharmaceutical companies including Pfizer, MSD and Transgene for the co-development of its drug candidates. BioInvent is headquartered in Lund, Sweden.
For a complete picture of BT-001’s drug-specific PTSR and LoA scores, buy the report here.